We need more studies in terms of more GLP-1s, more biologics, different types of patients, as you mentioned, maybe not the classic GLP-1 patient
And again, even that, you're talking in the heyday, maybe $2 billion for the whole industry, right
if you are still in the titration phase or on a subtherapeutic maintenance dose, increasing to the next level often restarts weight loss
Two phase III trials (EXPRESSIVE-10 and EXPRESSIVE-11) are ongoing, to evaluate the use on MK-8527 11mg tablet as once monthly oral PrEP in individuals 16 years and older
& Navarra, P
As the American Journal of Managed Care noted: "If Congress has not acted by the time the Bridge expires, patients who have been on these medications for a year and a half face an abrupt coverage cliff." What Changed and Why It Matters Now The program was announced months ago, but the funding-cliff question becomes practically urgent only when seniors are actively enrolling and taking their first doses which is now